LY2181308
- Generic Name
- LY2181308
- Drug Type
- Small Molecule
- Unique Ingredient Identifier
- 895O8QKF18
- Background
LY2181308 is investigated in clinical trials for treating solid tumors. LY2181308 is a solid. LY2181308 is directed against a molecular target called survivin. LY2181308 is known to target baculoviral IAP repeat-containing protein 5. LY2181308 is an anti-sense oligonucleotide that potently downregulated survivin expression in human cancer cells derived from lung, colon, breast, prostate, ovary, cervix, skin and brain.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 180
- Registration Number
- NCT01107444
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 154
- Registration Number
- NCT00642018
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain
A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT00620321
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States
A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2008-08-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 60
- Registration Number
- NCT00415155
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.